| 1. |
Hironaka S, Sugimoto N, Yamaguchi K, et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, openlabel, phase 2 trial. Lancet Oncol, 2016, 17(1): 99-108.
|
| 2. |
Bai T, Yokobori T, Altan B, et al. High STMN1 level is associated with chemo-resistance and poor prognosis ingastric cancer patients. Br J Cancer, 2017, 116(9): 1177-1185.
|
| 3. |
Verstegen MHP, Harker M, Water CVD, et al. Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology. World J Gastroenterology, 2020, 26(39): 6037-6046.
|
| 4. |
Hernandez-Unzueta I, Benedicto A, Olaso E, et al. Ocoxin oral solution? as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett, 2017, 13(6): 4002-4012.
|
| 5. |
Zhang D, He W, Wu C, et al. Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol, 2019, 10: 71. doi:10.3389/fimmu. 2019.00071.
|
| 6. |
Janjigian YY, Shitara K, Moehler M, et al. First line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro oesophageal junction, and oesophageal adenocarcinoma (Check Mate 649): a randomised, open label, phase 3 trial. Lancet, 2021, 398(10294): 27-40.
|
| 7. |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer, 2009, 45(2): 228-247.
|
| 8. |
Ajani JA, Bentrem DJ, Besh S, et al. National comprehensive cancer network. Gastric cancer, version 2. 2013:featured updates to the NCCN guidelines. J Natl Compr Canc Netw, 2013, 11(5): 531-546.
|
| 9. |
Smyth EC, Petty RD. Pembrolizumab versus paclitaxel in gastrooesophageal adenocarcinoma. Lancet, 2018, 392(10142): 97-98.
|
| 10. |
蘇昭然, 束寬山, 李坤峰, 等. 局部晚期不可切除胃癌轉化治療方案的初步研究. 中國 普外基礎與臨床雜志, 2021, 28(2): 248-251.
|
| 11. |
Rim C, Lee JA, Gong S, et al. A case of long-term complete remission of advanced gastric adenocarcinoma with liver metastasis. J Gastric Cancer, 2016, 16(2): 115-119.
|
| 12. |
陳博晉, 胡星怡, 趙菁文, 等. 免疫治療在胃癌新輔助治療中的研究進展. 腫瘤防治研究, 2022, 49(7): 727-732.
|
| 13. |
Derouazi M, Di Berardino Besson W, Belnoue E, et al. Novel cell-penetrating peptide-based vaccine induces robust CD4+ and CD8+ T cell-mediated antitumor immunity. Cancer Res, 2015, 75(15): 3020-3031.
|
| 14. |
陳衛昌, 石通國, 朱婧菡, 等. 胃腸腫瘤免疫治療進展. 腫瘤防治研究, 2022, 49(7): 639-643.
|
| 15. |
Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: A phase ii trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res, 2010, 16(5): 1662-1672.
|
| 16. |
Lyons TG, Ku GY. Systemic therapy for esophagogastric cancer: Immune checkpoint inhibition. Chin Clin Oncol, 2017, 6(5): 53. doi: 10.21037/cco.2017.09.03.
|
| 17. |
Tokunaga M, Ojyama S, Hiki N, et al. Can super extended lymph node dissection be justified for gastric cancer with pathologically positive paraaortic lymph nodes? Ann Surg Oncol, 2010, 17(8): 2031-2036.
|
| 18. |
Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification. Gastric cancer, 2016, 19(2): 329-338.
|
| 19. |
Yoshikawa T, Tanabe K, Nishikawa K, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol, 2014, 21(1): 213-219.
|
